Hyperdrive 35 Guidewire
Rapid-Medical , Ltd. · Decision date Sep 18, 2026
What did the FDA decide?
On September 18, 2026, FDA recorded decision SESE for K253146, submitted by Rapid-Medical, Ltd. The listed device is the Hyperdrive 35 Guidewire, classified under product code DQX with a Cardiovascular specialty. In 510(k) terms, SESE denotes a substantially equivalent determination, which is a clearance rather than a PMA approval; the source data do not state whether the submission was a new original or a subsequent one.
The document excerpt describes the Hyperdrive 35 Guidewire as a 0.035-inch diameter steerable guidewire with a deflectable tip intended to aid in accessing vasculature. A separate passage in the same excerpt describes the Glidewire as designed to direct a catheter to a desired anatomical location in the peripheral vasculature during diagnostic or interventional procedures. The source does not establish whether the Glidewire is the predicate device, a comparator, or unrelated content, and it does not identify specific components, materials, or changes reviewed.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 18, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K253146
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Rapid-Medical , Ltd.
- Product code
- DQX
- Decision code
- SESE
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Wire, Guide, Catheter.
- Applicant
- Rapid-Medical , Ltd.
- Product code
- DQX
- FDA device class
- 2
FDA decision timeline
K253146 received
Application receipt date recorded by FDA.
K253146 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DQX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Skycade Med Corporation | 510(k) clearance | Oct 16, 2026 | FDA | |
| Filmecc Co., Ltd. | 510(k) clearance | Sep 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Rapid-Medical , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Yokneam
Sources and methodology
- Original FDA record: K253146
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
